Chi Mong C Or, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · University Healthcare Alliance
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Or’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A172845 · Current
Licensed to practise in California · since 2021 · expires 2027-05-31 · University of British Columbia Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$230,762
Medicare paid this office $230,762 for 817 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 392 | $61,952 | $107 |
| Removal of cataract with insertion of prosthetic lens | 59 | $46,981 | $522 |
| Established patient complete exam of visual system | 175 | $20,124 | $115 |
| Short return visit (20+ min) | 142 | $15,205 | $81 |
| New patient visit (45+ min) | 99 | $13,356 | $135 |
See all 19 services
| Return visit (30+ min) | 392 | $61,952 | $107 |
| Removal of cataract with insertion of prosthetic lens | 59 | $46,981 | $522 |
| Established patient complete exam of visual system | 175 | $20,124 | $115 |
| Short return visit (20+ min) | 142 | $15,205 | $81 |
| New patient visit (45+ min) | 99 | $13,356 | $135 |
| Imaging of retina | 297 | $10,427 | $26 |
| Long return visit (40+ min) | 27 | $6,385 | $128 |
| Removal of recurring cataract in lens capsule using a laser | 15 | $4,640 | $309 |
| Imaging of optic nerve | 134 | $4,179 | $28 |
| New patient complete exam of visual system | 42 | $3,925 | $93 |
| Injection of drug into eye | 12 | $3,523 | $104 |
| Exam of visual field with extended testing | 42 | $2,347 | $52 |
| New patient visit (30+ min) | 16 | $1,647 | $103 |
| Measurement of corneal curvature and depth of eye | 53 | $1,503 | $27 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 24 | $1,306 | $38 |
| Ct scan of cornea | 24 | $439 | $18 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $270 | $15 |
| Imaging of retina with remote review by physician | 15 | $228 | $15 |
| Photography of content of eyes | 16 | $54 | $3 |
Procedures Medicare counted
| Cataract surgery | 137 | More than 79% of doctors who do this |
Who their Medicare patients are
817 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 17% · Women 61% · Also on Medicaid 8% · Health risk score 1.06. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 61% · Coronary heart disease 24% · Diabetes 21% · Cancer 16% · Atrial fibrillation 16% · Chronic kidney disease 15% · Heart failure 13% · Depression 11% · COPD 9% · Stroke 7% · Dementia 5%.
The office billed $1,283,258, Medicare allowed $306,778 and paid $230,762; for 2,155 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 817 | 2,155 | 77 | 1.06 | $1,283,258 | $230,762 |
| 2023 | 575 | 1,255 | 76 | 1.13 | $601,352 | $124,257 |
| 2022 | 231 | 451 | 74 | 1.11 | $107,218 | $31,134 |
| 2021 | 15 | 16 | 73 | 1.17 | $2,026 | $1,148 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 202 | $30,305 | $103 |
| Removal of cataract with insertion of prosthetic lens | 23 | $15,532 | $536 |
| New patient complete exam of visual system | 106 | $13,222 | $125 |
| Established patient complete exam of visual system | 107 | $12,096 | $111 |
| New patient visit (45+ min) | 84 | $11,451 | $136 |
| Short return visit (20+ min) | 93 | $8,940 | $78 |
| Imaging of retina | 170 | $5,137 | $22 |
| Long return visit (40+ min) | 11 | $3,325 | $133 |
| New patient visit (30+ min) | 27 | $2,314 | $86 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 19 | $934 | $39 |
| Imaging of optic nerve | 41 | $854 | $19 |
| Measurement of corneal curvature and depth of eye | 24 | $732 | $28 |
| Exam of visual field with extended testing | 20 | $594 | $28 |
| Ct scan of cornea | 18 | $372 | $19 |
| Imaging of retina with remote review by physician | 14 | $199 | $14 |
2022: 9 services
| Return visit (30+ min) | 90 | $9,199 | $89 |
| New patient visit (45+ min) | 60 | $7,524 | $125 |
| Imaging of retina | 112 | $2,948 | $23 |
| New patient complete exam of visual system | 15 | $1,861 | $124 |
| Short return visit (20+ min) | 24 | $1,690 | $63 |
| New patient visit (30+ min) | 15 | $1,129 | $75 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 13 | $520 | $37 |
| Imaging of optic nerve | 18 | $344 | $18 |
| Photography of the retina | 15 | $273 | $18 |
Medicaid work
$2,504 in 2024
Medicaid paid $2,504 for 83 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 27 | $1,480 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 56 | $1,025 |
| 2024 | 83 | 2 | 22 | $2,504 |
| 2023 | 113 | 2 | 20 | $2,490 |
| 2022 | 12 | 1 | 12 | $179 |
| 2020 | 77 | 2 | 18 | $659 |
| 2019 | 37 | 2 | 19 | $445 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 45 | $1,470 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 68 | $1,019 |
2022
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 12 | $179 |
2020
| Short return visit | 23 | $659 |
| Hospital outpatient clinic visit for assessment and management of a patient | 54 | $0 |
2019
| OFF/OP EST MAY X REQ PHY/QHP | 17 | $445 |
| Hospital outpatient clinic visit for assessment and management of a patient | 20 | $0 |
Drugs they prescribed that Part D paid
$137,795
Pharmacies billed $137,795 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 904) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
468 generic and 436 brand-name prescriptions · $137,795 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 30 | $24,035 | $801 |
| Rocklatan | 21 | $9,359 | $446 |
| Vyzulta | 22 | $8,684 | $395 |
| Lumigan | 13 | $6,674 | $513 |
| Mycophenolate Mofetil | 22 | $5,530 | $251 |
See all 19 drugs
| Restasis | 30 | $24,035 | $801 |
| Rocklatan | 21 | $9,359 | $446 |
| Vyzulta | 22 | $8,684 | $395 |
| Lumigan | 13 | $6,674 | $513 |
| Mycophenolate Mofetil | 22 | $5,530 | $251 |
| Cyclosporine | 13 | $3,950 | $304 |
| Dorzolamide-Timolol | 11 | $2,959 | $269 |
| Prednisolone Acetate | 54 | $2,744 | $51 |
| Brimonidine | 31 | $2,356 | $76 |
| Dorzolamide-Timolol | 155 | $2,342 | $15 |
| Valganciclovir | 14 | $2,338 | $167 |
| Latanoprost | 258 | $2,245 | $9 |
| Methotrexate | 11 | $793 | $72 |
| Dorzolamide | 29 | $598 | $21 |
| Prednisone | 40 | $497 | $12 |
| Moxifloxacin | 23 | $436 | $19 |
| Erythromycin | 17 | $221 | $13 |
| Timolol Maleate | 24 | $213 | $9 |
| Neomycin-Polymyxin-Dexameth | 16 | $172 | $11 |
Year by year
| 2024 | 904 | 264 | 0% (0) | 48% | $137,795 |
| 2023 | 499 | 189 | 0% (0) | 52% | $64,619 |
| 2022 | 331 | 109 | 0% (0) | 38% | $376,060 |
| 2021 | 254 | 68 | None | 36% | $35,012 |
| 2020 | 339 | 108 | 0% (0) | 33% | $25,202 |
| 2019 | 348 | 108 | 0% (0) | 31% | $17,285 |
| 2018 | 51 | 23 | 0% (0) | 29% | $2,435 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Mycophenolate Mofetil | 16 | $4,317 | $270 |
| Latanoprost | 183 | $3,033 | $17 |
| Dorzolamide-Timolol | 49 | $2,064 | $42 |
| Prednisolone Acetate | 28 | $1,501 | $54 |
| Methotrexate | 19 | $981 | $52 |
| Prednisone | 25 | $636 | $25 |
| Brimonidine | 14 | $412 | $29 |
| Dorzolamide | 14 | $348 | $25 |
| Neomycin-Polymyxin-Dexameth | 15 | $262 | $17 |
| Erythromycin | 18 | $190 | $11 |
| Timolol Maleate | 12 | $176 | $15 |
2022: 9 drugs
| Humira(Cf) | 11 | $107,820 | $9,802 |
| Mycophenolate Mofetil | 20 | $3,645 | $182 |
| Brimonidine | 25 | $2,497 | $100 |
| Dorzolamide-Timolol | 19 | $1,094 | $58 |
| Latanoprost | 61 | $1,018 | $17 |
| Methotrexate | 14 | $749 | $53 |
| Prednisone | 40 | $712 | $18 |
| Prednisolone Acetate | 17 | $661 | $39 |
| Erythromycin | 12 | $145 | $12 |
2021: 6 drugs
| Brimonidine | 40 | $2,747 | $69 |
| Latanoprost | 86 | $1,344 | $16 |
| Dorzolamide-Timolol | 40 | $948 | $24 |
| Prednisolone Acetate | 12 | $543 | $45 |
| Dorzolamide | 12 | $402 | $34 |
| Timolol Maleate | 12 | $82 | $7 |
2020: 6 drugs
| Brimonidine | 43 | $2,804 | $65 |
| Dorzolamide-Timolol | 47 | $2,124 | $45 |
| Latanoprost | 100 | $1,379 | $14 |
| Prednisolone Acetate | 19 | $1,007 | $53 |
| Dorzolamide | 17 | $521 | $31 |
| Timolol Maleate | 36 | $256 | $7 |
2019: 6 drugs
| Brimonidine | 69 | $2,488 | $36 |
| Latanoprost | 115 | $1,976 | $17 |
| Dorzolamide-Timolol | 44 | $1,765 | $40 |
| Prednisolone Acetate | 12 | $487 | $41 |
| Timolol Maleate | 34 | $328 | $10 |
| Dorzolamide | 12 | $298 | $25 |
2018: 1 drug
| Brimonidine | 11 | $300 | $27 |
Money from drug and device companies
$4,145 in 2025
| 2025 | 8 | 47 | $2,250 | $4,145 |
| 2024 | 6 | 33 | $1,275 | $2,724 |
| 2023 | 10 | 35 | None | $1,796 |
| 2022 | 11 | 25 | None | $1,530 |
| 2021 | 2 | 3 | None | $160 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mallinckrodt Hospital Products | Acthar | $1,980 | 12 payments
|
| Harrow Eye | Triesence | $739 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $507 | 17 payments
|
| Apellis Pharmaceuticals | Syfovre | $458 | 9 payments
|
| Ocular Therapeutix | Dextenza | $228 | 3 payments
|
| Astellas Pharma US | Izervay | $129 | 1 payment
|
See all 47 published payments
| ANI Pharmaceuticals | Meals · 2025-12-22 | Iluvien | $30 |
| Mallinckrodt Hospital Products | Meals · 2025-12-19 | Acthar | $12 |
| Mallinckrodt Hospital Products | Meals · 2025-12-08 | Acthar | $39 |
| Ocular Therapeutix | Meals · 2025-12-06 | Dextenza | $36 |
| Ocular Therapeutix | Meals · 2025-12-06 | Dextenza | $44 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-12-04 | Acthar | $1,550 |
| Apellis Pharmaceuticals | Meals · 2025-11-12 | Syfovre | $26 |
| ANI Pharmaceuticals | Meals · 2025-10-20 | Iluvien | $13 |
| Mallinckrodt Hospital Products | Meals · 2025-10-18 | Acthar | $108 |
| ANI Pharmaceuticals | Meals · 2025-10-18 | Purified Cortrophin Gel | $35 |
| Astellas Pharma US | Meals · 2025-10-16 | Izervay | $129 |
| ANI Pharmaceuticals | Meals · 2025-10-01 | Iluvien | $4 |
| ANI Pharmaceuticals | Meals · 2025-10-01 | Purified Cortrophin Gel | $23 |
| ANI Pharmaceuticals | Meals · 2025-08-26 | Iluvien | $31 |
| Apellis Pharmaceuticals | Meals · 2025-08-14 | Syfovre | $4 |
| Apellis Pharmaceuticals | Meals · 2025-08-13 | Syfovre | $25 |
| ANI Pharmaceuticals | Meals · 2025-08-04 | Iluvien | $30 |
| ANI Pharmaceuticals | Meals · 2025-07-21 | Iluvien | $8 |
| ANI Pharmaceuticals | Meals · 2025-07-21 | Iluvien | $19 |
| ANI Pharmaceuticals | Meals · 2025-07-10 | Purified Cortrophin Gel | $103 |
| Apellis Pharmaceuticals | Meals · 2025-07-09 | Syfovre | $20 |
| ANI Pharmaceuticals | Meals · 2025-07-02 | Yutiq | $27 |
| ANI Pharmaceuticals | Meals · 2025-06-19 | Yutiq | $34 |
| Apellis Pharmaceuticals | Meals · 2025-06-18 | Syfovre | $13 |
| Mallinckrodt Hospital Products | Meals · 2025-06-10 | Acthar | $37 |
| Harrow Eye | Consulting · 2025-06-05 | Triesence | $700 |
| Harrow Eye | Meals · 2025-05-22 | Vevye | $39 |
| Apellis Pharmaceuticals | Meals · 2025-05-19 | Syfovre | $3 |
| Apellis Pharmaceuticals | Meals · 2025-05-19 | Syfovre | $25 |
| Mallinckrodt Hospital Products | Meals · 2025-05-15 | Acthar | $37 |
| ANI Pharmaceuticals | Meals · 2025-05-12 | Yutiq | $30 |
| RxSight | Meals · 2025-04-18 | Rxsight Injector Handpiece | $23 |
| ANI Pharmaceuticals | Meals · 2025-04-07 | Yutiq | $27 |
| ANI Pharmaceuticals | Meals · 2025-03-26 | Yutiq | $26 |
| Mallinckrodt Hospital Products | Meals · 2025-03-18 | Acthar | $57 |
| Mallinckrodt Hospital Products | Meals · 2025-03-06 | Acthar | $33 |
| Ocular Therapeutix | Meals · 2025-03-05 | Dextenza | $147 |
| Mallinckrodt Hospital Products | Meals · 2025-03-04 | Acthar | $38 |
| ANI Pharmaceuticals | Meals · 2025-02-24 | Purified Cortrophin Gel | $43 |
| Johnson & Johnson Surgical Vision | Meals · 2025-02-11 | Tecnis Iol | $36 |
| Mallinckrodt Hospital Products | Meals · 2025-02-06 | Acthar | $4 |
| Mallinckrodt Hospital Products | Meals · 2025-02-06 | Acthar | $30 |
| Apellis Pharmaceuticals | Meals · 2025-02-05 | None | $281 |
| Apellis Pharmaceuticals | Meals · 2025-02-04 | Syfovre | $63 |
| Mallinckrodt Hospital Products | Meals · 2025-02-03 | Acthar | $35 |
| RxSight | Meals · 2025-01-21 | Rxsight Contact Lens | $47 |
| ANI Pharmaceuticals | Meals · 2025-01-08 | Purified Cortrophin Gel | $25 |
See earlier years (2024, 2023, 2022, 2021)
2024: $2,724
| ANI Pharmaceuticals | Purified Cortrophin Gel | $1,492 | 9 payments
|
| Mallinckrodt Hospital Products | Acthar | $508 | 11 payments
|
| Alimera Sciences | Yutiq | $264 | 3 payments
|
| Apellis Pharmaceuticals | Syfovre | $217 | 5 payments
|
| Astellas Pharma US | Izervay | $214 | 4 payments
|
| Oyster Point Pharma | Tyrvaya | $29 | 1 payment
|
2023: $1,796
| Mallinckrodt Hospital Products | Acthar | $320 | 16 payments
|
| Biogen | None | $310 | 5 payments
|
| Apellis Pharmaceuticals | Syfovre | $257 | 2 payments
|
| Alimera Sciences | Iluvien | $243 | 2 payments
|
| Astellas Pharma US | None | $200 | 3 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $135 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $119 | 1 payment
|
| Ocular Therapeutix | Dextenza | $90 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $70 | 3 payments
|
| Oyster Point Pharma | Tyrvaya | $53 | 1 payment
|
2022: $1,530
| Abbvie | Ozurdex | $249 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $223 | 7 payments
|
| Alimera Sciences | Iluvien | $180 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea | $169 | 2 payments
|
| Spark Therapeutics | None | $155 | 2 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $149 | 1 payment
|
| Exeltis USA | Purified Cortrophin Gel | $114 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $95 | 1 payment
|
| Genentech | Vabysmo | $94 | 1 payment
|
| Apellis Pharmaceuticals | None | $76 | 2 payments
|
| Biogen | None | $25 | 1 payment
|
2021: $160
| Mallinckrodt Hospital Products | Acthar | $147 | 2 payments
|
| Alcon Vision | Centurion | $12 | 1 payment
|
Professional record
- NPI
- 1639676000
- Licence
- CA A172845California A172845: Current · expires 2027-05-31
- Group
- Stanford Health Care · University Healthcare Alliance
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0108X (207WX0108X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2018-04-11
- NPI last updated
- 2025-11-21
- NPI record certified
- 2025-11-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 31 Massachusetts Ave Apt B4, Boston, MA, 02115